COMMUNIQUÉ RÉGLEMENTÉ
News
-
-
COMMUNIQUÉ RÉGLEMENTÉ
BILAN SEMESTRIEL DU CONTRAT DE LIQUIDITE 2° SEMESTRE 2023
Bilan semestriel contrat de liquidité de TONNELLERIE FRANCOIS FRERES confié à Kepler Cheuvreux avec détails sur comptes, transactions et volumes échangés conformément à la décision AMF n°2021-01. Informations financières et contacts -
COMMUNIQUÉ DE PRESSE
Argo Blockchain PLC Announces £7.8 million ($9.9 million) Placing
Argo Blockchain plc, a global leader in cryptocurrency mining, has announced a successful raise of gross proceeds of £7.8 million ($9.9 million) through the issue of new ordinary shares. The proceeds will be used for working capital, repayment of indebtedness, and general corporate purposes. The new ordinary shares will be admitted to the Official List and trading on the Main Market of the London Stock Exchange PLC. For more information, visit www.argoblockchain.com. -
COMMUNIQUÉ RÉGLEMENTÉ
bioMérieux acquires LUMED to reinforce its software portfolio in the fight against antimicrobial resistance
bioMérieux has acquired LUMED, a software company specializing in clinical decision support systems to optimize antimicrobial prescriptions and monitor healthcare-associated infections. This acquisition reinforces bioMérieux's commitment to combat antimicrobial resistance and improve infection prevention and control through advanced software solutions. -
COMMUNIQUÉ RÉGLEMENTÉ
AMOEBA CONFIRME SON ÉLIGIBILITÉ AU DISPOSITIF PEA-PME
AMOÉBA confirme son éligibilité au dispositif PEA-PME pour l'année 2024, permettant l'intégration de ses actions dans les portefeuilles PEA PME. La biotech se concentre sur le traitement du risque microbiologique dans les secteurs de l'eau, de la protection des plantes et de la santé -
COMMUNIQUÉ RÉGLEMENTÉ
AMOEBA : Déclaration du nombre total de droits de vote et du nombre d’actions composant le capital au 31 décembre 2023
Déclaration du nombre total de droits de vote et du nombre d’actions composant le capital au 31 décembre 2023 pour Amoéba, société cotée sur Euronext Growth. Ambition de devenir un acteur majeur du traitement du risque microbiologique dans les secteurs de l’eau, de la protection des plantes et de la santé. Commercialisation de produits biocontrôle prévue dès 2025 -
COMMUNIQUÉ RÉGLEMENTÉ
Le Groupe PLC, soutenu par l'IDI et Stags, élargit son portefeuille de galéniques avec l’acquisition de Creapharm Cosmetics
Le Groupe PLC acquiert Creapharm Cosmetics, CDMO spécialiste du façonnage de produits cosmétiques. Creapharm permet à PLC de diversifier son offre et de renforcer sa position sur le marché des CDMO. L'acquisition inclut le réinvestissement de la famille Placet -
COMMUNIQUÉ DE PRESSE
Argo Blockchain PLC Announces December Update/Management Change/Share Allotment
Argo Blockchain plc, a global leader in cryptocurrency mining, has reported a 4% increase in daily Bitcoin production in December 2023, along with a 25% rise in mining revenue compared to the previous month. The company also disclosed changes in management and share allotment, as well as the grant of equity awards. Argo Blockchain plc is a dual-listed blockchain technology company focusing on large-scale cryptocurrency mining and sustainability. For more information, visit www.argoblockchain.com. -
COMMUNIQUÉ DE PRESSE
Court of Appeals for the Federal Circuit Hears Oral Arguments on Patent Dispute
Bausch Health Companies Inc. and its gastroenterology business Salix Pharmaceuticals presented oral arguments at the U.S. Court of Appeals for the Federal Circuit regarding the matter of Salix Pharmaceuticals, LTD et al v. Norwich Pharmaceuticals, Inc. No ruling was issued following the oral arguments. The company continues to advocate for the safety of patients benefiting from XIFAXAN® (rifaximin) 550 mg tablets, indicated for hepatic encephalopathy recurrence and irritable bowel syndrome with diarrhea. Salix Pharmaceuticals focuses on the prevention and treatment of gastrointestinal diseases for over 30 years and markets its products to U.S. health care providers. On the other hand, Bausch Health Companies Inc. is a global diversified pharmaceutical company with a mission to improve people's lives through various health care products, primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, and eye health. The news release contains forward-looking statements about Bausch Health's future performance and the appeal with respect to intellectual property. The actual results are subject to certain risks and uncertainties. For more information, visit www.bauschhealth.com and connect with them on Twitter and LinkedIn. -
COMMUNIQUÉ DE PRESSE
Smart IMS Strengthens Executive Team, Insurtech Leader Anil Chitale Appointed as Managing Director
Smart IMS, a leading technology service and solutions provider, has appointed Anil Chitale as the Managing Director. With over 35 years of experience in the U.S. Insurance industry, Anil's addition to the executive team is expected to further strengthen the company's offerings in the Insurance space. The company aims to leverage Anil's expertise to enhance its business growth and provide world-class technology solutions to its clients in the fast-changing technology and regulatory environment. Smart IMS is headquartered in Plainsboro, New Jersey and offers a wide range of global technology solutions including Application & Infrastructure Management services, Unified Communications, and Life Sciences and Insurance services.
